Lineage Cell The Stock Price, News & Analysis

Lineage Cell Therapeutics has announced updates to the 2nd Annual Spinal Cord Injury Investor Symposium (SCIIS), scheduled for June 26-27, 2024, in San Diego. The event aims to enhance SCI research and treatment by bringing together companies, regulators, patients, and investors. The symposium will feature expanded sessions including clinical discussions with Neuralink and preclinical insights from Axonis, Novoron, Sania, and Rewire Medical. Key speakers include experts from RUSH University, the Miami Project to Cure Paralysis, and the Christopher & Dana Reeve Foundation, among others. The event seeks to foster collaboration, raise awareness, and attract investment in SCI treatment development.

Lineage Cell Therapeutics, Inc. reported its first quarter 2024 financial results, revealing significant milestones and data updates on the OpRegen program. The company established a new services agreement with Genentech to support ongoing development and presented positive clinical data at industry events. Additionally, Lineage announced the initiation of the OPC1 clinical study for spinal cord injuries and received a grant from CIRM. The appointment of Dr. Charlotte Hubbert as VP of Corporate Development and a strong balance sheet with $43.6 million in cash, cash equivalents, and marketable securities highlight the company's progress and potential.

Lineage Cell Therapeutics, Inc. presented 24-month visual acuity results of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The data showed BCVA gains of +5.5 letters at 24 months in Cohort 4 patients, with additional gains observed in patients with extensive OpRegen bleb coverage. The study suggested that OpRegen may counteract RPE cell dysfunction and loss in GA by supporting remaining retinal cells, with effects lasting at least 2 years post-administration.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) will announce its first quarter 2024 financial results on May 9, 2024. The company, focused on developing allogeneic cell therapies, will host a conference call to discuss the results and provide a business update.

Lineage Cell Therapeutics, Inc. (LCTX) received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) to support the 2nd Annual Spinal Cord Injury Investor Symposium. The symposium aims to accelerate development in spinal cord injury research and treatments by bringing together stakeholders in the field. It will focus on discussing current and future treatment alternatives, raising investor awareness, and broadening investment into spinal cord injury. The event will feature speakers from various organizations and will take place on June 26 and 27, 2024, in La Jolla, CA.

Lineage Cell Therapeutics, Inc. announces the passing of its Chairman, Mr. Alfred D. Kingsley, and appoints Michael H. Mulroy, J.D., as the new Chairman of the Board of Directors. Mr. Kingsley's significant contributions to the company are acknowledged, and Mr. Mulroy brings extensive experience in biotech and biopharma to his new role.